KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacira BioSciences (PCRX) Depreciation & Amortization (CF) (2016 - 2025)

Historic Depreciation & Amortization (CF) for Pacira BioSciences (PCRX) over the last 16 years, with Q3 2025 value amounting to $21.2 million.

  • Pacira BioSciences' Depreciation & Amortization (CF) rose 463.14% to $21.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $90.9 million, marking a year-over-year increase of 1959.44%. This contributed to the annual value of $78.8 million for FY2024, which is 424.88% up from last year.
  • According to the latest figures from Q3 2025, Pacira BioSciences' Depreciation & Amortization (CF) is $21.2 million, which was up 463.14% from $27.3 million recorded in Q2 2025.
  • In the past 5 years, Pacira BioSciences' Depreciation & Amortization (CF) ranged from a high of $30.4 million in Q4 2022 and a low of $4.9 million during Q1 2021
  • In the last 5 years, Pacira BioSciences' Depreciation & Amortization (CF) had a median value of $19.6 million in 2023 and averaged $18.1 million.
  • Its Depreciation & Amortization (CF) has fluctuated over the past 5 years, first soared by 32605.68% in 2022, then crashed by 3920.61% in 2023.
  • Pacira BioSciences' Depreciation & Amortization (CF) (Quarter) stood at $13.1 million in 2021, then skyrocketed by 132.64% to $30.4 million in 2022, then crashed by 39.21% to $18.5 million in 2023, then grew by 14.92% to $21.2 million in 2024, then dropped by 0.24% to $21.2 million in 2025.
  • Its last three reported values are $21.2 million in Q3 2025, $27.3 million for Q2 2025, and $21.2 million during Q1 2025.